Engot-Ov-6/Trinova-2: randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in Women with recurrent partially platinum-sensitive or resistant ovarian cancer.
Affiliation
Universitӓtsklinik fuer Gynaekologie und Geburtshilfe, Medizinische Universitӓt Innsbruck, Innsbruck, AustriaIssue Date
2015